Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2020

View Archived Issues

Helping hand for protein sorting prevents AD

Mutant TP53 affects fat metabolism

Skin-deep defense may be good enough for arboviruses

New phase I trial studies monoclonal antibody CIS-43LS against malaria

Topline data from phase III VELOS-2 study of HL-036

Blueberry Therapeutics receives IND clearance from the FDA for BB-2603

TRuE-AD2 pivotal phase III study of ruxolitinib cream meets primary endpoint

First patient dosed in phase I study of SY-5609

FDA approves first human trials of Myeliviz for PET imaging in MS

V-4020, a novel VEEV vaccine with increased safety and stability

cis-Regulatory elements of the FOXA1 plexus as therapeutic targets in prostate cancer

Results from phase I/II COMPOSER study of crovalimab

Janssen presents phase II results for daratumumab in relapsed AL amyloidosis

Melanocortin MC2 receptor antagonists disclosed by Crinetics Pharmaceuticals

Saint Louis University, Indalo Therapeutics patent integrin alphavbeta1/alpha5beta1 antagonists

Idorsia Pharmaceuticals discovers OX1/OX2 receptor antagonists

Servier, Vernalis identify new ubiquitin carboxyl-terminal hydrolase 7 inhibitors

Nuclear receptor ROR-gamma antagonists discovered at Sunshine Lake Pharma

Trovagene presents update on phase Ib/II trial of onvansertib

Feisty old folks: Sprightly genomes bring insights into healthy aging, early-onset illness

Enrollment open in first-in-human study of CC-97540 in NHL

Phase II study of AKCEA-ANGPTL3-LRx meets primary endpoint of significant triglyceride lowering

Clover begins development of recombinant subunit vaccine for 2019-nCoV

CytoDyn explores use of leronlimab for novel coronavirus

Avacta demonstrates proof of concept for TMAC platform in animal model of cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...